



Patent

Attorney Docket No: CPR-00101.P.1-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)

MIYAZAKI)

Examiner: AUDET, Maury

Application Number: 10/602,035)

Group Art Unit: 1654

Filed: June 23, 2003)

For: METHODS FOR PREVENTING)

ADHESION FORMATION USING)

PROTEASE INHIBITORS)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action mailed December 13, 2005, Applicant respectfully submits the following elections without traverse. Applicant submits this response within six (6) month of the Office Action mailing date, and encloses the fee for a five (5) month extension of time.

05/30/2006 SFELEKE1 00000024 10602035

01 FC:2255

1080.00 OP

CPR-00101.P.1-US

1. ELECTION

Applicant elects the invention of Group I. Applicant also elects the peptide Suc-Val-Pro-Phe^P(OPh)₂. As to the species election, Applicant elects any pharmaceutically acceptable carrier.
These elections are made without traverse.

The above-identified patent application has been examined for restriction purposes only.
The Examiner has set forth the following groups:

| Group No. | Claims | Subject Matter |
|-----------|--------|--|
| I | 1-32 | Methods for preventing or reducing adhesion formation between tissue surfaces |
| II | 33-34 | A composition comprising at least one protease inhibitor or a combination of at least one protease inhibitor and a delivery vehicle which maintains an effective local concentration of said inhibitor |

Because the methods described allegedly may be practiced by a myriad of compositions, the Examiner has restricted the claims to 2 distinct and independent inventions. Applicant elects the invention of group I which includes claims 1-32 without traverse.

In addition, because an overlapping / coextensive search of the disclosed peptides and compounds is allegedly not possible, the Examiner has required that the Applicant select a single peptide or compound. Applicant elects the peptide Suc-Val-Pro-Phe^P(OPh)₂.

Also, the Examiner has required that the Applicant select a single delivery vehicle. As to this species election, Applicant elects a pharmaceutically acceptable carrier.


Claims 1-32 are readable upon the elected invention and species.

Applicant respectfully submits that the claims are ready for examination and in condition for allowance.

Please apply any charges not covered, or any credits, to Deposit Account Number 501321 in the name of David R. Preston & Associates, APC having Customer Number 24232.

Respectfully submitted,

Date: May 24, 2006

A handwritten signature in black ink, appearing to read 'David R. Preston', written over a horizontal line.

David R. Preston
Reg. No. 38,710

David R. Preston & Associates
12625 High Bluff Drive
Suite 205
San Diego, CA 92130

Telephone: 858.724.0375
Facsimile: 858.724.0384